JoanneLorraineBlumMDPhD
Oncology • Maple City, MIProfessor (Affiliated), Internal Medicine, TX A&M Univ Coll of Med Andy and Joan Horner Endowed Chair in Breast Cancer Research, BUMC, Retired as of 2/28/2022
Dr. Blum is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2255 W School Lake Rd
Maple City, MI 49664Phone+1 469-767-1687
Summary
- I am a board certified oncologist and trained at the University of Michigan. My practice was restricted to breast cancer. I was also the Director of the Hereditary Cancer Risk Program at the Baylor-Sammons Cancer Center at Baylor University Medical Center in Dallas, TX
Education & Training
University of MichiganPhD, Cellular and Molecular Biology, 1984 - 1987
University of MichiganFellowship, Hematology and Medical Oncology, 1983 - 1987- University of MichiganResidency, Internal Medicine, 1980 - 1982
- Michael Reese Hospital and Medical CenterInternship, Internal Medicine, 1979 - 1980
University of Maryland School of MedicineClass of 1979- University of PennsylvaniaBA, Biology, Summa cum laude, 1971 - 1975
Certifications & Licensure
TX State Medical License 1988 - 2026
MI State Medical License 1981 - 2025
MD State Medical License 1979 - 1982- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Andy and Joan Horner Endowed Chair in Breast Cancer Research Baylor University Medical Center, Dallas, TS, 2016
- ASCO Clinical Trials Participation Award ASCO, 2008
- Distinguished Young Research Award University of Texas Southwestern Medical Center, 1990
- Join now to see all
Clinical Trials
- TAC Versus TC for Adjuvant Breast Cancer Start of enrollment: 2007 May 29
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
- A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Publications & Presentations
PubMed
- Real-world quality-of-life of patients with HR+/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS.Gabrielle B Rocque, Joanne L Blum, Yan Ji, Timothy Pluard, John Migas
Breast Cancer Research and Treatment. 2024-11-25 - Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial.Debu Tripathy, Joanne L Blum, Meghan S Karuturi, Steven McCune, Sobha Kurian
The Oncologist. 2024-10-30 - 3 citationsNeoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.Melinda L Telli, Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen
Breast Cancer. 2024-09-01
Journal Articles
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA MutationJoanne Blum, MD, The New England Journal of Medicine
Press Mentions
10 Dec COVID-19 Impacts Breast Cancer Study Data AcquisitionDecember 10th, 2020
Expert Shares Insight on Improved DFS with TaxAC in HER2-Negative Breast CancerJuly 5th, 2016
Anthracycline Regimen Superior in HER2-Negative Breast CancerJune 30th, 2016- Join now to see all
Grant Support
- Molecular Analyses of Breast Cancers from Individuals with Hereditary Cancer SyndromesBaylor Research Institute BRI and Translational Genomics Research Institute (TGen)2016–2018
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
